Skip to content
MadInfo
Health1 min read

SESARAM boosts anti-hemorrhagic drug stock with investment over 700 thousand euros

The Regional Government has redistributed budgetary burdens for the acquisition of Eftrenonacog Alfa, ensuring treatment for patients at SESARAM.

The Regional Secretariat for Health and Civil Protection has published Ordinance no. 179/2026, which proceeds with the redistribution and amendment of budgetary burdens for the acquisition of anti-hemorrhagic drugs, specifically the medication Eftrenonacog Alfa, intended for the Health Service of the Autonomous Region of Madeira, EPERAM (SESARAM).

The global base price for the acquisition is 706,212.15 €, plus VAT at a rate of 6%. The financial burden has been fully allocated to the 2026 fiscal year, ensuring the continuity of specialized healthcare required for users of the regional service.

Share this article

Related articles